Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 3/20 | 0.52 |
| ▸ | NSD2 | O96028 | 2/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | S100A4 | P26447 | 5/20 | 0.42 |
| ▸ | CDC25B | P30305 | 3/20 | 0.42 |
| ▸ | PTPRC | P08575 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10044895 | 0.86 | KMT2A (0.52) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL2910234 | 0.77 | TDP1 (0.70) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL14380254 | 0.77 | TDP1 (0.70) | TDP2NSD2PAX8ABL1PLCG1 | |
| Acetic Acid SCHEMBL5323363 | 0.72 | TDP2 (0.76) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL12589660 | 0.72 | GAA (0.47) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL22929974 | 0.72 | PTPRC (0.67) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL22930033 | 0.72 | TDP1 (0.62) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL11046636 | 0.72 | DRD2 (0.44) | TDP2NSD2GAAKMT2AMEN1 | |
| SCHEMBL14257666 | 0.70 | TDP2 (0.40) | TDP2NSD2PAX8ABL1PLCG1 | |
| SCHEMBL10253722 | 0.70 | ALDH1A1 (0.41) | KMT2APDK2CYP1A2CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9526769-B2 | Macrocylic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-8268776-B2 | mixture of cytochrome P450 monooxygenase inhibitor and protease inhibitor for anti-hepatitis C viral treatment; including other active drugs as interferon, ribavarin, and adamantine | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268776-B2 | mixture of cytochrome P450 monooxygenase inhibitor and protease inhibitor for anti-hepatitis C viral treatment; including other active drugs as interferon, ribavarin, and adamantine | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8193346-B2 | Process for making macrocyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193346-B2 | Process for making macrocyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| WO-2009073780-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20080181868-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-07-31 | — | — | US | disclosed |
| US-20070281884-A1 | Macrocyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281884-A1 | Macrocyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080181868-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | HCCS, CPN1, HPN | TDP2 4521/4885NSD2 1534/4885PAX8 4734/4885 |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | HCCS, CPN1, HPN | TDP2 4521/4885NSD2 1534/4885PAX8 4734/4885 |
| US-20070281884-A1 | Macrocyclic oximyl hepatitis C protease inhibitors | HCCS, HPN, CYP3A4 | TDP2 4484/4885NSD2 1406/4885PAX8 4652/4885 |
| US-20090156800-A1 | PROCESS FOR MAKING MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | PREP, HCCS, PEPD | TDP2 4538/4885NSD2 3345/4885PAX8 4205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.